Log in

Log in


NLRC4 Mutation and XIAP Deficiency:
The Swiss-based company AB2 Bio is conducting a clinical study in North America (U.S.A. and Canada), and recruiting patients in several regions. The aim of this Phase III study is to assess the efficacy and safety of Tadekinig alfa in patients with monogenic, interleukin-18 driven autoinflammation caused by NLRC4-MAS mutation or XIAP deficiency.

More information about the study can be found on the Study Info Sheet,  Press Release or the entry on

Multi-institution Phase Ib/II study to determine the efficacy and tolerability of a response-adapted regimen incorporating ruxolitinib (JakafiĀ®), dexamethasone and etoposide as frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis or as salvage therapy for patients with relapsed/refractory HLH. The trial is coordinated by the North American Consortium of Histiocytosis  (NACHO) with enrollment at St. Jude and 9 additional sites throughout the United States.

More information can be found at: HLHRUXO and

If there is a study that you would like to see included on this page, it must be one that can be found on  Please contact the Secretariat's office at for more information.

Office: +1 (856) 589-6606
Fax: +1 (856) 589-6614

Histiocyte Society
332 N Broadway
Pitman, NJ 08071 USA

Powered by Wild Apricot Membership Software